Drugs and patents in ATC class N01BA - Esters of aminobenzoic acid

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
IHEEZO	chloroprocaine hydrochloride
CHLOROPROCAINE HYDROCHLORIDE	chloroprocaine hydrochloride
NESACAINE	chloroprocaine hydrochloride
NESACAINE-MPF	chloroprocaine hydrochloride
>Tradename	>Generic Name

Last updated: August 1, 2026

N01BA covers ester local anesthetics derived from aminobenzoic acid, including procaine, tetracaine, chloroprocaine, and metabutethamine. The class is mature, largely generic, and characterized by low active-ingredient patent risk. Commercial competition is shaped more by injectable manufacturing, sterile supply, institutional contracting, formulation availability, and regulatory compliance than by exclusivity.

The most commercially relevant products are chloroprocaine hydrochloride injection, tetracaine hydrochloride products, and procaine hydrochloride products. Core composition-of-matter patents for these molecules expired decades ago. Current patent exposure is generally limited to specific formulations, delivery systems, combinations, or manufacturing processes rather than the active ingredients themselves.

What drugs are included in ATC Class N01BA?

ATC N01BA identifies esters of aminobenzoic acid used as local anesthetics. The class is separate from amide anesthetics such as lidocaine, bupivacaine, ropivacaine, and mepivacaine.

ATC code	Active ingredient	Main dosage forms	Principal clinical uses	Commercial status
N01BA01	Metabutethamine	Injectable local anesthetic	Regional and local anesthesia	Limited or discontinued availability in many markets
N01BA02	Procaine	Injectable solution; dental preparations in some markets	Local and regional anesthesia	Mature generic market
N01BA03	Tetracaine	Injectable, ophthalmic, topical, and spinal products	Spinal, ophthalmic, and topical anesthesia	Mature market with formulation-specific products
N01BA04	Chloroprocaine	Injectable solution	Epidural, spinal, and regional anesthesia	Active hospital and specialty market
N01BA52	Combinations of esters	Various	Local anesthesia	Marketed only in selected jurisdictions

The ATC system is maintained by the World Health Organization Collaborating Centre for Drug Statistics Methodology. Classification does not establish patent protection, FDA approval, or commercial availability in a particular country. (WHO Collaborating Centre for Drug Statistics Methodology, 2024)

When do N01BA drugs lose exclusivity?

The core molecules in N01BA have no meaningful remaining composition-of-matter exclusivity in the United States or major European markets.

Procaine was introduced in the early 20th century, tetracaine in the 1930s, chloroprocaine in the 1950s, and metabutethamine in the mid-20th century. Any original compound patents expired long before the modern Hatch-Waxman framework became relevant.

Active ingredient	Original commercialization period	Core patent position	Current exclusivity driver
Procaine	Early 1900s	Expired	Manufacturing, supply, and product registration
Tetracaine	1930s	Expired	Dosage form and market-specific regulatory status
Chloroprocaine	1950s	Expired	Injectable formulation, sterile manufacturing, and supply
Metabutethamine	Mid-20th century	Expired	Product availability and regulatory maintenance

FDA approval of a generic local anesthetic does not create a new molecular exclusivity period. A sponsor may obtain limited protection for a new formulation, route, device, or method of use, but those rights do not restore exclusivity for the underlying ester anesthetic.

What patents protect procaine, tetracaine, and chloroprocaine?

The commercially relevant patent landscape is concentrated in four areas:

Injectable formulations with revised concentrations, preservatives, or pH control.
Sterile manufacturing and container-closure systems.
Topical, ophthalmic, dental, or transdermal delivery.
Combination products and procedure-specific methods of use.

Procaine patent landscape

Procaine hydrochloride is an old generic anesthetic. Its principal commercial forms are injectable solutions and, in selected markets, dental preparations. The active ingredient is not protected by a live U.S. composition-of-matter patent.

Potential patent issues relate to:

Preservative-free single-dose ampules.
Concentration and packaging configurations.
Dental cartridge systems.
Combination products containing procaine and other agents.
Foreign-market product registrations and formulation patents.

Procaine has limited branded-market strength because clinicians have shifted substantial use toward amide anesthetics and newer ester products. Its remaining commercial value is linked to low-cost supply and established use in specific procedures.

Tetracaine patent landscape

Tetracaine is marketed in several dosage forms, which creates more formulation diversity than for procaine. The relevant products include injectable tetracaine for spinal anesthesia, ophthalmic preparations, and topical anesthetics.

Patent activity may concern:

Preservative-free spinal formulations.
Ophthalmic solutions with controlled concentration.
Gel, cream, spray, or film delivery systems.
Combination products with other topical anesthetics.
Packaging designed to reduce contamination or dosing errors.

The core tetracaine molecule has no remaining patent barrier. Formulation patents can matter commercially only where the product is differentiated and the patent claims cover the marketed dosage form.

Chloroprocaine patent landscape

Chloroprocaine has become the most commercially relevant N01BA molecule in the U.S. hospital market because of renewed use in neuraxial anesthesia and short-duration regional anesthesia.

The active ingredient remains off-patent. Commercial barriers center on:

Sterile injectable production.
Preservative-free presentation.
Concentration and vial or ampule configuration.
Stability and container-closure performance.
Institutional procurement contracts.
FDA regulatory compliance for injectable products.

Modern chloroprocaine products can obtain regulatory protection for a particular product presentation, but that protection does not block an appropriately designed competing chloroprocaine injection.

What is the Orange Book status of N01BA drugs?

The Orange Book lists FDA-approved drug products and certain patents submitted by sponsors under the Hatch-Waxman framework. Older injectable anesthetics often have limited or no Orange Book patent listings because their approvals predate modern patent-reporting practices and because the marketed products are generic.

Product category	Typical Orange Book position	Practical implication
Legacy procaine injection	No active listed patent barrier expected	ANDA or applicable abbreviated pathway can proceed without a core patent challenge
Generic tetracaine injection	Product-specific listing; usually no core patent barrier	Entry depends on approval, supply, and formulation requirements
Generic chloroprocaine injection	Limited or no meaningful active patent estate for the molecule	Sterile manufacturing and approval are the principal barriers
Ophthalmic or topical tetracaine	Patent status depends on the specific product and formulation	A formulation patent may affect one dosage form without protecting all tetracaine products
Combination products	Potentially separate patent and exclusivity analysis	The combination, device, or delivery system must be assessed independently

The FDA Orange Book should be reviewed at the product and application-number level because patent listings can differ between dosage forms, strengths, and sponsors. The absence of a listed patent does not eliminate non-Orange Book patent risk, including formulation, process, device, or foreign patent rights. (U.S. Food and Drug Administration, 2025a)

Which companies are challenging N01BA products?

Competition is fragmented among generic injectable manufacturers, specialty pharmaceutical companies, hospital suppliers, and regional drug makers. The market does not have a single dominant challenger comparable to the concentrated competition seen in protected specialty drugs.

Potential suppliers include:

Generic injectable manufacturers with FDA-approved sterile facilities.
Specialty anesthesia companies.
Contract manufacturers supplying hospital and ambulatory surgery channels.
Regional manufacturers in Europe, Asia, Latin America, and the Middle East.
Sponsors of ophthalmic and topical anesthetic products.

The principal competitive event is usually a new abbreviated application or product registration, not a Paragraph IV litigation campaign. A competitor can often enter without challenging a live compound patent because the relevant molecules are long off-patent.

What Paragraph IV challenges affect N01BA drugs?

Paragraph IV risk is low for the core N01BA molecules. A Paragraph IV certification is relevant only when an ANDA applicant seeks approval for a product associated with a listed patent. Since procaine, tetracaine, and chloroprocaine have no commercially meaningful active-ingredient patents remaining, the most likely Paragraph IV issues would involve:

A newly listed formulation patent.
A delivery device or container patent.
A combination product.
A method-of-use patent with claims relevant to the proposed label.
A patent listed for a specific branded presentation rather than the molecule.

A Paragraph IV filing would not normally be required to launch a conventional generic ester anesthetic where no relevant listed patent remains. FDA ANDA applicants must still address any patents and exclusivities listed for the reference product. (U.S. Food and Drug Administration, 2025a; U.S. Food and Drug Administration, 2025b)

What formulations are protected by N01BA patents?

Formulation protection is more relevant than molecule protection. The main areas include:

Preservative-free injectable products

Preservative-free formulations are important for spinal and epidural use. A sponsor may seek claims covering concentration, pH, excipient selection, stability, or packaging. These claims can protect a product presentation without preventing competitors from making the same active ingredient in a different formulation.

Ophthalmic tetracaine

Ophthalmic products may contain claims directed to:

Reduced irritation.
Improved stability.
Specific buffering systems.
Unit-dose delivery.
Preservative-free packaging.
Enhanced corneal penetration.

These patents are product-specific and do not create broad protection for tetracaine.

Topical anesthetic systems

Creams, gels, sprays, films, and compounded delivery systems can generate patent claims around:

Penetration enhancers.
Polymer matrices.
Controlled release.
Combination anesthetics.
Dosing systems.
Application devices.

The commercial value of these rights depends on whether the formulation has a clinically meaningful advantage and whether physicians, hospitals, or consumers will pay for it.

How strong is the N01BA patent estate?

The patent estate is weak for the active ingredients and moderate in selected delivery niches.

Patent category	Strength	Commercial relevance
Composition of matter	Very weak; expired	No meaningful barrier
Basic injectable formulation	Weak to moderate	Can affect a specific presentation
Preservative-free spinal formulation	Moderate in narrow claims	Relevant to neuraxial products
Ophthalmic delivery	Moderate	Relevant where a branded product has differentiated packaging or stability
Topical controlled release	Moderate in narrow claims	Relevant to specialty or consumer products
Manufacturing process	Variable	More important as a trade-secret and quality issue than as a blocking patent
Device and packaging	Moderate	Can delay copying of a particular product system
Method of use	Weak to moderate	Usually limited by label scope and clinical practice

The strongest barriers are operational. Sterile injectables require validated aseptic processing, reliable active pharmaceutical ingredient supply, extractables and leachables controls, container-closure testing, and consistent regulatory compliance.

What FDA regulatory status applies to N01BA products?

N01BA products are regulated according to dosage form, route, strength, and intended use. FDA pathways include:

Abbreviated New Drug Applications for eligible generic products.
New Drug Applications for new formulations or clinical presentations.
Supplemental applications for changes to an approved product.
Drug listing and establishment registration requirements.
Current good manufacturing practice obligations under 21 C.F.R. Parts 210 and 211.

Injectable products face higher development and manufacturing requirements than conventional topical products. A sponsor must demonstrate quality attributes such as sterility, strength, identity, particulate control, endotoxin limits, container integrity, and stability.

Chloroprocaine products intended for spinal or epidural use also face clinical and labeling scrutiny tied to route-specific safety. The regulatory burden can discourage entry even when patent barriers are absent.

What generic entry risks exist for N01BA drugs?

Generic entry risk is high for conventional injectable and topical products because:

Core patents are expired.
Clinical use is established.
Generic regulatory pathways are available.
Switching is often acceptable in hospital procurement.
Buyers prioritize price, supply continuity, and quality.

Entry risk is lower where the product requires:

A specialized preservative-free presentation.
Low-volume sterile filling.
Complex ophthalmic packaging.
A differentiated delivery system.
Reliable supply of a difficult-to-source active ingredient.
Specialized regulatory or clinical data.

The main launch risk is therefore execution rather than litigation. A new entrant may obtain approval but fail to secure hospital contracts, maintain supply, or meet production economics.

What patent litigation affects N01BA products?

N01BA has limited recent patent litigation compared with newer anesthetic and pain products. Litigation risk is more likely to arise from:

A branded formulation patent.
A device or packaging patent.
Trade-secret disputes involving sterile manufacturing.
Regulatory disputes over generic labeling.
Product liability claims involving contamination, dosing, or route-specific use.

The absence of major compound litigation reflects the age of the molecules and the generic structure of the market. A diligence review should search federal patent litigation databases, FDA patent listings, and national patent registers for the particular formulation and sponsor rather than treating the ATC class as a single patent family.

Are there licensing deals for N01BA drugs?

Large strategic licensing transactions are uncommon. Procaine and tetracaine are commodity or mature generic products. Chloroprocaine can support more commercially relevant arrangements because of its hospital use and specialized injectable supply requirements.

Typical transactions involve:

Regional commercialization rights.
Contract manufacturing and supply agreements.
Transfer of an approved application.
In-licensing of an ophthalmic or topical delivery system.
Distribution agreements with hospital suppliers.
Acquisition of a portfolio of legacy injectable products.

Transaction value is driven by manufacturing access, regulatory approvals, geographic rights, and supply contracts rather than by long-lived molecular patent protection.

How does N01BA compare with amide local anesthetics?

N01BA products compete primarily with amide anesthetics, not only with other ester anesthetics.

Factor	Ester anesthetics, N01BA	Amide anesthetics
Core patent status	Long expired	Mostly expired for older molecules; newer products may have formulation rights
Clinical positioning	Selected spinal, topical, ophthalmic, and regional uses	Broad hospital, dental, and surgical use
Market concentration	Fragmented	Larger and more diversified
Supply risk	Higher for some sterile products	Variable, with multiple established suppliers
Generic entry	Generally straightforward	Straightforward for older molecules
Differentiation	Formulation and route	Duration, safety profile, delivery, and combination products
Litigation exposure	Low	Higher where branded formulations or devices exist

Amide anesthetics generally have broader utilization and stronger purchasing infrastructure. N01BA products retain value where their pharmacology, onset, duration, or clinical history fits a specific procedure.

What is the geographic coverage of N01BA patents and products?

Patent protection for the core molecules has expired globally. Geographic differences now arise from:

National marketing authorization.
Local product availability.
Manufacturing-site approvals.
Pharmacopoeial requirements.
Hospital tender systems.
Importation controls.
National reimbursement and procurement rules.

The same active ingredient may be widely available in one country and absent in another. European Union markets may have separate national product histories despite centralized regulatory structures. In emerging markets, local registration and supply-chain access can be more important than patent clearance.

What revenue exposure exists for N01BA products?

Revenue exposure is generally low at the molecule level but can be meaningful for suppliers with concentrated hospital portfolios. The main revenue drivers are:

Unit volume rather than high price.
Institutional contracts.
Product availability during shortages.
Sterile manufacturing capacity.
Product breadth across anesthetics and emergency medicines.
Geographic distribution.

N01BA products do not typically support blockbuster revenue. Commercial exposure is highest when a company has a leading position in a limited-supplier injectable market or controls a differentiated ophthalmic or topical presentation.

Key Takeaways

N01BA includes procaine, tetracaine, chloroprocaine, and metabutethamine.
Core compound patents expired decades ago.
Conventional generic entry risk is high.
Orange Book patent exposure is generally limited and product-specific.
Formulation, packaging, delivery systems, and sterile manufacturing are the main remaining IP and commercial barriers.
Chloroprocaine has the strongest current hospital-market relevance within the class.
Tetracaine has the broadest formulation diversity, particularly in ophthalmic and topical products.
Procaine is commercially mature and faces strong substitution from amide anesthetics.
Paragraph IV litigation is not the principal market risk.
Supply continuity, sterile manufacturing, regulatory compliance, and institutional contracting determine commercial success.

Frequently Asked Questions

Does chloroprocaine have an active composition patent?

No. Chloroprocaine is an old ester local anesthetic, and its original composition-of-matter protection expired long ago. Any current patent risk would relate to a particular formulation, delivery system, or manufacturing process.

Can a generic company launch procaine without a Paragraph IV certification?

Yes, if the proposed product has no relevant listed patent or the applicant addresses any applicable listed patent through the required ANDA certification. The molecule itself is not protected by a current compound patent.

Are preservative-free tetracaine products patentable?

Yes. A sponsor may obtain narrow claims covering a specific preservative-free formulation, concentration, stability profile, packaging configuration, or delivery method. Those rights would not ordinarily cover all tetracaine products.

Is N01BA subject to biosimilar competition?

No. Procaine, tetracaine, chloroprocaine, and metabutethamine are small-molecule drugs, not biologics. Competition proceeds through generic-drug and national abbreviated-approval pathways rather than biosimilar regulation.

Which N01BA product has the greatest commercial opportunity?

Chloroprocaine has the strongest opportunity in specialized injectable and neuraxial anesthesia markets. The opportunity depends on sterile manufacturing capacity, hospital contracting, supply reliability, and differentiated product presentation rather than on molecular patent exclusivity.

References

U.S. Food and Drug Administration. (2025a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
U.S. Food and Drug Administration. (2025b). Abbreviated new drug application (ANDA): Generics. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
U.S. Food and Drug Administration. (2024). Current good manufacturing practice for drugs. https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations
World Health Organization Collaborating Centre for Drug Statistics Methodology. (2024). ATC/DDD index: N01BA Esters of aminobenzoic acid. https://atcddd.fhi.no/atc_ddd_index/
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

Drugs in ATC Class N01BA

Drugs in ATC Class: N01BA - Esters of aminobenzoic acid

N01BA Esters of Aminobenzoic Acid: Market Dynamics, Patent Landscape, and Generic Entry Risk